Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
Holding ACAD?
Track your performance easily
ACAD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.15 - $32.59
Previous Close$17.66
Volume1.53M
Average Volume (3M)1.36M
Market Cap
$2.85B
Enterprise Value$2.27B
Total Cash (Recent Filing)$626.37M
Total Debt (Recent Filing)$40.42M
Price to Earnings (P/E)22.9
Beta1.29
Next Earnings
Mar 03, 2025EPS Estimate
$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.77
Shares Outstanding166,391,891
10 Day Avg. Volume1,642,570
30 Day Avg. Volume1,363,793
Standard Deviation0.14
R-Squared0.02
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)5.68
Price to Sales (P/S)3.20
Price to Cash Flow (P/CF)28.50
P/FCF Ratio28.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit3.31
Enterprise Value/Ebitda15.72
Forecast
1Y Price Target
$27.42Price Target Upside55.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
ACADIA Pharmaceuticals News
PremiumCompany Announcements
Acadia Pharmaceuticals Sees Revenue Growth and Strategic AdvancesBulls Say, Bears Say
Bulls Say
Sales PerformanceNuplazid sales of $159.2mn beat analyst expectations and consensus estimates.
Successful Marketing StrategyA direct to consumer campaign for Nuplazid, featuring actor Ryan Reynolds, has been launched to accelerate growth in the future.
Unique Market PositionDaybue remains the only approved product for Rett syndrome, offering a longer-term opportunity that remains underappreciated.
Bears Say
EarningsDaybue net sales of $91.2M missed the analyst's estimate of $93.1M.
Financial PerformanceDaybue sales appear to be flattening after a strong initial launch, with slow volume growth expected going forward.
GuidanceDaybue 2024 guidance was narrowed to the lower end of the previous guidance.
---
Ownership Overview
24.14% Insiders
14.80% Mutual Funds
2.47% Other Institutional Investors
41.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $14.15 and its highest was $32.59 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
Currently, no data Available
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Mar 03, 2025 which is in 114 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported $0.2 earnings per share for the quarter, beating the consensus estimate of $0.138 by $0.062.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is $0.23.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 165,876,050 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.2 in its last earnings report, beating expectations of $0.138. Following the earnings report the stock price went up 8.93%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 697M.
---
ACADIA Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.42 (55.27% Upside)
$27.42 (55.27% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 75%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 33.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.84%
12-Months-Change
Fundamentals
Return on Equity
27.36%
Trailing 12-Months
Asset Growth
54.44%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
---
ACAD Company Deck
---
ACAD Earnings Call
Q3 2024
0:00 / 0:00
---
ACAD Stock 12 Month Forecast
Average Price Target
$27.42
▲(55.27% Upside)
Technical Analysis
Best Analysts Covering ACAD
1 Year
1 Year Success Rate
15/25 ratings generated profit
1 Year Average Return
+7.60%
assigned a buy rating 3 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +7.60% per trade.
---